Literature DB >> 33688224

Relationship Between Serum Amyloid A1 (SAA1) Gene Polymorphisms Studies with Obesity in the Saudi Population.

Khalid Khalaf Alharbi1, Amal F Alshammary1, Omar Sammar Aljabri1, Imran Ali Khan1.   

Abstract

PURPOSE: Limited studies have shown positive and negative associations of serum amylase A1 (SAA1) gene in childhood obesity, previously showed the relation with obesity in different ethnicity. The current study therefore investigated the impact of single nucleotide polymorphisms present in the SAA1 gene on subjects of Saudi obesity. PARTICIPANTS AND METHODS: In this case-control study, we selected 140 subjects of Saudi population and categorized them into 83 cases of obesity and 57 healthy controls. Genotyping was performed with quantitative/real time-polymerase chain reaction in the SAA1 gene for rs11603089A/G, rs4638289A/T and rs7131332A/G polymorphisms.
RESULTS: In rs11603089 polymorphism, co-dominant model (AG vs AA+GG; OR-2.23 [95% CI:1.02-4.86]; p=0.04) and rs4638289 polymorphism, a disparity in significance was observed between the homozygous variant (TT vs AA; OR-16.8 [95% CI: 2.06-136.8]; p=0.0009), dominant model (AT+TT vs AA; OR-2.57 [95% CI: 1.28-5.19]; p=0.007), recessive model (TT vs AA+AT; OR-11.36 [95% CI: 1.45-89.06]; p=0.004) and allelic frequency for (T vs A: OR-2.35 [95% CI: 1.39-3.98]; p=0.001) between the obesity cases and control subjects. However, statistical correlations did not reveal the rs7131332A/G polymorphism either (p>0.05).
CONCLUSION: In conclusion, rs4638289 polymorphism was associated with risk allele and dominant model with obesity subjects. Further additional studies were warranted.
© 2021 Alharbi et al.

Entities:  

Keywords:  SAA1 gene; obesity; rs11603089; rs4638289 and rs7131332 polymorphisms

Year:  2021        PMID: 33688224      PMCID: PMC7935349          DOI: 10.2147/DMSO.S294948

Source DB:  PubMed          Journal:  Diabetes Metab Syndr Obes        ISSN: 1178-7007            Impact factor:   3.168


Introduction

Obesity (OMIM: 601,665) is reported as one of the inherited and multiple metabolic disorders in humans.1,2 Calmly, obesity represents a major health problem globally with 0.4 billion people affected.3 Visceral adipose tissue in human is more closely associated with metabolic disease than subcutaneous adipose tissue.4 The rate of obesity has almost tripled globally in the last decades, with an estimated 1.9 billion adults overweight.5 Although obesity has become a pandemic and a major burden in one of the high-income countries in Kingdom of Saudi Arabia.6 Body Mass Index (BMI) is widely used for diagnosing obesity. While BMI has an association with body fat mass that may be overestimated in people with high muscle mass. Similarly, BMI was revealed since not all obese people experience metabolic disorders commonly associated with obesity.7 With an enormous chronic metabolic disorder, involves insulin resistance, dyslipidemia, type 2 diabetes, obesity will progress and manifests the diseases associated with obesity and will increase cardiovascular morbidity and mortality, which further leads towards heart failure, arrhythmia and sudden cardiac death.8 The relationship between observational, case-control, genetic linkage, candidate gene, and genome-wide association (GWAS) studies between candidate obesity genes and body weight-related obesity has been documented with nearly 600 genes, and chromosomal regions have been confirmed to participate in the regulation of BMI and energy metabolism. There are numerous genes associated with human obesity including serum amylase A1 (SAA1) with the role of obesity.9 Zhang et al10 reported the relationship between obesity and SAA1 gene. Obsession also affects systemic inflammatory responses, including moderately elevated serum levels of the acute phase protein Amyloid A (SAA), which are suggested to contribute to the development of type 2 diabetes and tolerance to insulin. SAA has been studied in several ways, but its function is still quite unclear. SAA is an apolipoprotein and is mainly associated with circulating HDL particles. SAA is proposed to include processes such as cholesterol, lipolytic and opsonic transport and the production of pro-inflammatory cytokines.11 In addition to being a plasma sensitive phase protein, SAA is an apolipoprotein that can replace the main apolipoprotein HDL-C, apolipoprotein A1, especially in the acute phase reaction.10 For highly inducible acute phase SAA proteins in the acute phase response, SAA1 code. Human SAA1 is best recognized among all known SAA proteins for its physiologically sound and gene-polymorphic functions. SAA1 encodes 122 pre-protein amino acids, including the 18-amino acid peptide signal. With just a few amino acids, the genetic materials of these coding alleles vary at positions 52, 57, 60 and 72.12 The rs11603089, rs4638289 and rs7131332 polymorphisms or single nucleotide polymorphisms (SNPs) have a functional role without any protein effect. SAA1 gene is acute-phase encoding in SAAs. Earlier reports in the effect of a SAA1 gene polymorphism on SAA plasma concentration and another GWAS revealed that the SAA1 gene polymorphism is substantially linked to an increase in SAA plasma.13 Limited genes were screened in the Saudi population with the obesity subjects. There were no studies have been implemented in the SAA1 gene in the obesity subjects in the Saudi population. So, therefore present study was aimed to investigate the relationship between SAA1 gene polymorphisms in the Saudi obese subjects.

Participants and Methods

Sample Selection

This is a case–control study performed in the College of Applied Medical Sciences after obtaining the ethical grant within the college premises (CAMS054-3839). This study was conducted in accordance with the Declaration of Helsinki. In this study, we have recruited 83 obesity cases and 57 matching controls. The inclusion criteria of the obese subjects were based on body mass index (BMI >30kg/m2) without other medical complications and for controls it will be Saudi subjects without obesity or non-BMI (<25kg/m2). The exclusion criteria of the obesity cases were low BMI, non-Saudi subjects and with other disease complications and in controls will be the non-Saudi subjects and obese patients with BMI >30kg/m2. All the participants signed the informed consent form before participation in this study. Age, gender and BMI details as well as other medical complications were recorded in this study.

Molecular Analysis

Genomic DNA was extracted from EDTA blood using Genomic purification kit and NanoDropTM spectrophotometer was performed to quantify the concentration of genomic DNA prior to performing the quantitative polymerase chain reaction (qPCR). Genotyping methodology was performed as per the Alharbi et al14 studies for rs11603089 [A/G], rs4638289 [A/T] and rs7131332 [A/G] using VIC and FAM probes as described.

Statistical Analysis

Statistical analysis was performed as per Khan et al15 studies using the data analysis. Continuous variables were expressed as mean±standard deviation (m±SD) and categorical variables were expressed as percentages. A p value <0.05 was considered as statistically significant. Linkage Disequilibrium (LD) was performed with R software using three SNPs involved in this study.

Results

Non-Genotypic Data Analysis

In this case–control study, a total of 140 Saudi subjects were enrolled. Among them, 83 obesity cases and 57 control subjects were confirmed. Among 140 Saudi subjects, 44% were females and 56% were males. Table 1 describes the anthropometric characteristics and related family histories of the involved Saudi subjects. All the involved participants’ mean age was found to be 30.4±6.4 in obesity cases and 24.4±4.6 in the control subjects, which was found to statistically significant (p=0.001). Gender (p=0.91) and height (p=0.30) was found to be non-significant association (p>0.05). Both the weight and BMI were found to be statistically significant (p<0.001). However, all the participants were free of family histories for both the metabolic and cardiac diseases (p=1.0).
Table 1

Clinical Characteristics Between Obesity Cases and Healthy Controls

S. No.Baseline CharacteristicsObesity Cases (n=83)Controls (n=57)P-value
1Age (Years)30.4±6.424.4±4.60.001
2Gender (Male: Female)47 (56.6%): 36 (43.4%)32 (56.1%): 25 (43.9%)0.91
3Weight (kgs)80.4±18.155.07±7.28<0.001
4Height (cms)160.7±8.51162.1±7.10.30
5BMI (kg/m2)30.9±5.6120.89±1.86<0.001
6Family History of Metabolic diseases0(0%)0(0%)1.0
7Family History of Cardiac diseases0(0%)0(0%)1.0
Clinical Characteristics Between Obesity Cases and Healthy Controls

HWE Analysis

The HWE was calculated and confirmed the genotype distribution with control subjects only in rs7131332 (χ2=0.35; p=0.55); whereas in both rs11603089 (χ2=4.22; p=0.03) and rs463829 (χ2=3.03; p=0.08). The details were shown in Table 2.
Table 2

Hardy Weinberg Equilibrium Analysis

S.NoGeners Numberχ2P-valueHWE Criteria
1SAA1rs116030894.220.03Non-HWE criteria
2SAA1rs46382893.030.08Non- HWE criteria
3SAA1rs71313320.350.55HWE criteria
Hardy Weinberg Equilibrium Analysis

Genotype Analysis

Table 3 describes genotype and allele frequencies between obesity cases and controls. Genotyping was performed for rs11603089, rs4638289 and rs7131332 SNPs between the obesity cases and controls. The rs7131332 SNPs did not show any significant associations between genotypes, dominant model and allele frequencies between cases and controls (rs7131332; AG+GG- [OR: 1.08 (0.55–2.13); p=0.80], AG vs AA- [OR-0.84 (0.41–1.70); p=0.63] and G vs A- [OR-0.75 (0.45–1.25); p=0.27]. However, rs11603089 polymorphism showed association only with co-dominant model ie, AG vs AG+GG- [OR: 2.23 (1.02–4.86); p=0.04], and for rs4638289 SNP was found to be statistically significant in dominant mode [OR-2.57 (1.28–5.19); p=0.007], recessive model [OR-11.36 (1.45–89.06); p=0.004], TT vs AA [OR-16.8 (2.06–136.8); p=0.0009] and allele mode of frequencies (T vs A- [OR-2.35 (1.39–3.98); p=0.001]).
Table 3

Genotype and Allele Frequencies in rs11603089, rs4638289 and rs7131332 Polymorphisms in SAA1 Gene in Obesity Cases and Control Subjects

SNPsGenotypes/AllelesCases (n=83)Controls (n=57)Odds Ratio95% CIP-value
rs11603089AA49 (59.0)41 (71.9)ReferenceReferenceReference
AG31 (37.3)12 (21.1)2.160.98–4.730.05
GG3 (3.6)4 (7.0)0.620.13–2.960.66
AG+GG vs AA34 (40.9)16 (28.1)1.770.86–3.670.11
AG vs AA+GG31 (37.3)12 (21.1)2.231.02–4.860.04
GG vs AA+AG3 (3.6)4 (7.0)0.490.10–2.310.36
A129 (77.7)94 (82.5)ReferenceReferenceReference
G37 (22.3)20 (17.5)1.340.73–2.470.33
rs4638289AA25 (30.1)30 (52.6)ReferenceReferenceReference
AT44 (53.0)26 (45.6)2.030.98–4.160.05
TT14 (16.9)1 (1.8)16.82.06–136.80.0009
AT+TT vs AA58 (69.9)27 (47.4)2.571.28–5.190.007
AT vs AA+TT44 (53.0)26 (45.6)1.340.68–2.640.38
TT vs AA+AT14 (16.9)1 (1.8)11.361.45–89.060.004
A94 (56.6)86 (75.4)ReferenceReferenceReference
T72 (43.4)28 (24.6)2.351.39–3.970.001
rs7131332AA39 (47.0)23 (40.4)ReferenceReferenceReference
AG40 (48.2)28 (49.1)0.840.41–1.700.63
GG4 (4.8)6 (10.5)0.390.10–1.540.17
AG+GG vs AA44 (53.0)29 (50.9)1.080.55–2.130.80
AG vs AA+GG40 (48.2)28 (49.1)0.960.49–1.890.91
GG vs AA+AG4 (4.8)6 (10.5)0.430.11–1.600.19
A118 (71.1)74 (64.9)ReferenceReferenceReference
G48 (28.9)40 (35.1)0.750.45–1.250.27
Genotype and Allele Frequencies in rs11603089, rs4638289 and rs7131332 Polymorphisms in SAA1 Gene in Obesity Cases and Control Subjects

Linkage Disequilibrium Analysis

Delta Coefficient (D′) specified LD analysis was calculated in the SAA1 gene both for patients and controls for the three SNPs (rs11603089, rs4638289, and rs7131332). No similarity between the three SNPs was found (Figure 1; Table 4).
Figure 1

Linkage disequilibrium continuum of the genomic region in chromosome 11 position between 3 SNPs (rs11603089, rs4638289, and rs7131332) in SAA1 gene.

Table 4

Linkage Disequilibrium Analysis with SNPs Involved in This Study

rs11603089rs4638289rs7131332
rs1160308910.1320.16
rs46382890.13210.154
rs71313320.160.1541
Linkage Disequilibrium Analysis with SNPs Involved in This Study Linkage disequilibrium continuum of the genomic region in chromosome 11 position between 3 SNPs (rs11603089, rs4638289, and rs7131332) in SAA1 gene.

Discussion

The aim of the present study was to assess the relationship between SAA1 gene polymorphisms in the Saudi obese subjects. No significant association was found with the studies three SNPs (rs11603089, rs4638289 and rs7131332) used in this study with obesity, however rs4638289 polymorphism in the SAA1 gene was correlated with the possibility of obese but not with the prospect of overweight in the dominant mode of inheritance (p=0.007) as well as allelic frequencies (p=0.001). Our study is in agreement with the findings of other global studies on obesity.10 The results of our study are almost in accordance with the Zhang et al8 studies with polymorphisms rs11603089 and rs4638289, but not with the polymorphism rs7131332. The genotype frequencies for AA, AG and GG were found to be 68%, 28% and 4% in rs11603089 SNP and were reported to be 59%, 37.3% and 3.6% respectively in our study. With 33% in AA, 44% in AT and 23% in TT genotypes, the 2nd SNP (rs4638289) was reported; whereas in our study, it was reported to be 30.1%, 53% and 16.9% respectively. The AA, AG and GG genotypes were found to be 24%, 58% and 18% with the rs7131332 polymorphism, and our findings were stated to be 47%, 48.2% and 4.8%, respectively. The polymorphisms rs11603089, rs4638289 and rs7131332 in the SAA1 gene were studied in Kawasaki disease subjects with limited ethnicity.10,16 The Ying et al13 studies were conducted with rs4638289 and rs7131332 polymorphisms in Kawasaki disease. With our current study findings, the genotype frequencies in the case subjects were almost identical. The disease differs, however, from the studies of Ying et al13 In addition to obesity, the additional SNPs in SAA1 gene were used in other diseases in global populations.17,18 In Chinese women diagnosed with Osteoporosis in rs12218 polymorphism, Feng et al14 studies were conducted and this polymorphism was not performed to compare genotype findings in our current research. Yashiro et al15 studies were conducted in adult onset still disease with rs1136743 and rs1136747 polymorphisms with SAA1 gene and these related polymorphisms were not conducted in this current study. None of the meta-analysis studies of obesity and SAA1 gene polymorphism were conducted in the global population. This may be due to the limited case–control studies performed in the different ethnicities. However, Zhao et al19 performed a meta-analysis study focused only on BMI and SAA levels with various global studies but not with the genotyping analysis. Obesity is considered to be an inherited disorder that is related to both genetic and non-genetic ie, environmental factors may play an important role. Genetic factors play an important role in obesity, particularly when regulating weights.20 Obesity is strongly associated with Saudi Arabia because of various factors. The prevalence of obesity was confirmed at 52.9% in 2017 and 59.5% was expected to rise in 2022.6 The genetic influence on obesity may be due to the involvement of multiple SNPs linked to obesity and its associated phenotypes. There are multiple gene polymorphisms, observational, and numerous studies of obesity in the different regions of the Saudi Arabia have been carried out. SAA1 was originally described as an antisera-recognized serum component against amyloid fibrils, known as AA. Subsequently, it was found that SAA1 acts as a major precursor of AA and is an HDL apolipoprotein in the acute-phase serum. The human SAA1 is best characterized by its physiological roles and gene polymorphisms between all known SAA proteins. Human SAA1 is located in the chromosome 11 short arm and comprises 4 exons with exon 2–4 coding sequences, respectively.12 The current studies’ strength was to optimize Saudi subjects, opt for three SNPs and performed qPCR. One of the study’s major limitations was the limited sample size. Missing the enrolled biochemical data was one of the limitations of this study.

Conclusion

The present study concludes that SAA1 gene was associated with rs11603089, rs4638289 polymorphisms in the Saudi obese population. Future research to carry out the meta-analysis studies should be carried out in other ethnicities.
  19 in total

1.  Genetic polymorphisms of serum amyloid A1 and coronary artery disease risk.

Authors:  X Xie; Y-T Ma; Y-N Yang; X-M Li; Y-Y Zheng; F Liu; X Ma; Z-Y Fu; Z-X Yu; Y Chen; B-D Chen; Y Huang
Journal:  Tissue Antigens       Date:  2015-02-06

Review 2.  Serum amyloid A1: Structure, function and gene polymorphism.

Authors:  Lei Sun; Richard D Ye
Journal:  Gene       Date:  2016-03-03       Impact factor: 3.688

Review 3.  Genetic variants influencing effectiveness of weight loss strategies.

Authors:  Sophie Deram; Sandra M F Villares
Journal:  Arq Bras Endocrinol Metabol       Date:  2009-03

4.  New evidence for associations between vitamin D receptor polymorphism and obesity: case-control and family-based studies.

Authors:  Songcheng Yu; Xing Li; Fei Yu; Zhenxing Mao; Yan Wang; Yuan Xue; Hualei Sun; Yue Ba; Chongjian Wang; Wenjie Li
Journal:  J Hum Genet       Date:  2019-12-09       Impact factor: 3.172

5.  Genetic polymorphisms and weight loss in obesity: a randomised trial of hypo-energetic high- versus low-fat diets.

Authors:  Thorkild I A Sørensen; Philippe Boutin; Moira A Taylor; Lesli H Larsen; Camilla Verdich; Liselotte Petersen; Claus Holst; Søren M Echwald; Christian Dina; Søren Toubro; Martin Petersen; Jan Polak; Karine Clément; J Alfredo Martínez; Dominique Langin; Jean-Michel Oppert; Vladimir Stich; Ian Macdonald; Peter Arner; Wim H M Saris; Oluf Pedersen; Arne Astrup; Philippe Froguel
Journal:  PLoS Clin Trials       Date:  2006-06-30

6.  Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still's disease.

Authors:  Makiko Yashiro; Hiroshi Furukawa; Tomoyuki Asano; Shuzo Sato; Hiroko Kobayashi; Hiroshi Watanabe; Eiji Suzuki; Tadashi Nakamura; Tomohiro Koga; Toshimasa Shimizu; Masataka Umeda; Fumiaki Nonaka; Yukitaka Ueki; Katsumi Eguchi; Atsushi Kawakami; Kiyoshi Migita
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

7.  Depot-specific adipocyte-extracellular matrix metabolic crosstalk in murine obesity.

Authors:  Clarissa Strieder-Barboza; Nicki A Baker; Carmen G Flesher; Monita Karmakar; Ayush Patel; Carey N Lumeng; Robert W O'Rourke
Journal:  Adipocyte       Date:  2020-12       Impact factor: 4.534

8.  Associations of SAA1 gene polymorphism with lipid lelvels and osteoporosis in Chinese women.

Authors:  Zheng-Ping Feng; Xiao-Yu Li; Rong Jiang; Hua-Cong Deng; Mei Yang; Qin Zhou; Wen-Jun Que; Jia Du
Journal:  Lipids Health Dis       Date:  2013-03-22       Impact factor: 3.876

9.  No evidence for a role of adipose tissue-derived serum amyloid a in the development of insulin resistance or obesity-related inflammation in hSAA1(+/-) transgenic mice.

Authors:  Sofie Ahlin; Maja Olsson; Bob Olsson; Per-Arne Svensson; Kajsa Sjöholm
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

10.  The Presence of Urinary Ketones according to Metabolic Status and Obesity.

Authors:  Bo Reum Kim; Jeong Woo Seo; Sang Man Kim; Kyu Nam Kim; Nam Seok Joo
Journal:  J Korean Med Sci       Date:  2020-08-10       Impact factor: 2.153

View more
  4 in total

1.  Effect of Genetic Variations in the ADIPOQ Gene on Susceptibility to Type 2 Diabetes Mellitus.

Authors:  May Salem Al-Nbaheen
Journal:  Diabetes Metab Syndr Obes       Date:  2022-09-07       Impact factor: 3.249

2.  Associations of TCF7L2 rs11196218 (A/G) and GLP-1R rs761386 (C/T) Gene Polymorphisms with Obesity in Chinese Population.

Authors:  Tiantian Xu; Mengmeng Liu; Qingjing Liu; Bian Wang; Min Wang; Minli Qu; Xin Chen; Jing Wu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-01       Impact factor: 3.168

3.  Contribution of genetic variant identified in HHEX gene in the overweight Saudi patients confirmed with type 2 diabetes mellitus.

Authors:  Mohammed Alfaifi
Journal:  Saudi J Biol Sci       Date:  2021-10-22       Impact factor: 4.219

4.  Elevated CTSL Gene Expression Correlated with Proinflammatory Cytokines in Omental Adipose Tissue of Patients with Obesity.

Authors:  Qiong Zhou; Yankun Zhu; Chun Li; Zhiqiang Li; Zhe Tang; Baohong Yuan; Xiaodan Wang; Shengqingyu Zhang; Xinan Wu
Journal:  Diabetes Metab Syndr Obes       Date:  2022-07-30       Impact factor: 3.249

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.